Currently, heart disease remains the leading cause of death while cardiac arrest is one of the most devastating conditions patients and their families have to face. Despite all efforts to explain management of cardiac arrest and implementation of advanced cardiovascular life support (ACLS), survival rates post cardiac arrest remains at 23.9 % in adults and 40.2% in children (AHA, 2012). Nurses undergo extensive ACLS training every two years. While algorithms, administration of emergency drugs, and procedures seem to be followed appropriately, rationales of the latter are often not well understood. In this paper pharmacokinetics and pharmacodynamics, adverse effects of ACLS drugs, drug-drug interactions of intervention drugs, and anticipated long-term adverse effects post cardiac arrest will be discussed. In the case study of JG, the patient went into cardiac arrest on the way to the hospital and he was pronounced after a full code had been performed for three hours. The cause of his cardiac arrest in regards to heart rhythm is unclear and no medical history is available.
Table of Contents
Introduction
ACLS Guidelines
Clinical Pharmacology of Emergency Drugs
Vasopressin versus Epinephrine - Amiodarone versus Lidocaine
Pharmacodynamics
Adverse Reactions
Disease Interaction According to the FDA
Drug-Drug Interactions
Review of Literature
Consideration of Other Commonly Prescribed Cardiac Drugs
Conclusion
References
Research Objectives and Themes
This paper examines the clinical pharmacology of emergency drugs used in Advanced Cardiovascular Life Support (ACLS), focusing on their pharmacodynamics, adverse reactions, and complex drug-drug interactions. The objective is to analyze the rationale behind current ACLS administration guidelines, evaluate the efficacy of various pharmacological interventions, and address the potential long-term complications associated with these life-saving medications in cardiac arrest patients.
- Pharmacological profiles of epinephrine, vasopressin, amiodarone, and lidocaine.
- Evaluation of ACLS treatment algorithms and their efficacy in return of spontaneous circulation (ROSC).
- Analysis of systemic adverse reactions and interactions with commonly prescribed cardiac medications.
- Clinical considerations for drug selection in patients with comorbidities and pre-existing medical histories.
Excerpt from the Book
Pharmacodynamics
Epinephrine, a sympathomimetic catecholamine acting on both alpha and beta-adrenergic receptors, benefits patients during cardiac arrest due to its receptor stimulating properties (FDA, n.d.). Epinephrine’s alpha-adrenergic effects lead to systemic vasoconstriction, and subsequently to increased myocardial and cerebral blood flow (AHA, 2000). Epinephrine has a rapid onset and short duration of action with a half-life of 2 minutes (Food and Drug Administration [FDA], n.d.).
Vasopressin, a noradrenergic polypeptide antidiuretic hormone that causes contraction of vascular and other smooth muscles, benefits patients in cardiac arrest due to stimulation of V1 and V2 receptors. Stimulation of V1 receptors leads to peripheral, coronary, and renal vasoconstriction, while stimulation of V2 receptors leads to vasodilation, and subsequent reduction of end-organ hypoperfusion. Vasopressin also leads to increased cerebral blood flow by vasodilation. It is suspected that vasopressin administration during cardiac arrest leads to decreased incidences of long-term neurological damage (Wenzel, 2004). Vasopressin increases systemic vascular resistance and mean arterial pressure, therefore decreases heart rate and cardiac workload (FDA, n.d.). Onset and peak are rapid and half-life is 10-20 minutes.
Amiodarone, a class III antiarrhythmic, benefits patients in cardiac arrest by blocking calcium, sodium and potassium channels, which slows conduction and prolongs refractoriness of the atrioventricular (AV) node. Amiodarone has vasodilatory effects triggering sympathetic activity, which lead to decreased cardiac workload and subsequent decreased myocardial oxygen consumption. Amiodarone has, in comparison with lidocaine, very little negative inotropic activity. IV amiodarone has a rapid onset, half-life in blood plasma is relatively short, exact time is unknown (Giardina & Passman, 2014).
Lidocaine, a class Ib antiarrhythmic drug, benefits patients in cardiac arrest by decreasing depolarization and automaticity of ventricular cells and by increasing ventricular fibrillation threshold. Onset of IV lidocaine is immediate and half-life is 10 minutes (Karch, 2012).
Summary of Chapters
Introduction: Provides an overview of cardiac arrest and the necessity of understanding the rationale behind ACLS drug administration despite established training protocols.
ACLS Guidelines: Outlines the current American Heart Association recommendations for resuscitation, including CPR, defibrillation, and pharmacological management with vasopressors and anti-arrhythmics.
Clinical Pharmacology of Emergency Drugs: Details the pharmacological properties and risks of specific emergency medications used in cardiac arrest scenarios.
Vasopressin versus Epinephrine - Amiodarone versus Lidocaine: Compares the mechanisms of action, adverse effects, and interaction profiles of key vasopressor and anti-arrhythmic agents.
Review of Literature: Surveys existing clinical studies on the survival outcomes associated with different pharmacological approaches in cardiac arrest.
Consideration of Other Commonly Prescribed Cardiac Drugs: Discusses how medications patients are already taking interact with ACLS drugs and potentially complicate resuscitation efforts.
Conclusion: Summarizes the findings, emphasizing the importance of informed drug selection based on patient history while acknowledging the inherent risks of emergency pharmacological interventions.
References: Lists the academic and medical sources used to support the analysis of ACLS protocols and drug interactions.
Keywords
Cardiac arrest, ACLS, epinephrine, vasopressin, amiodarone, lidocaine, pharmacodynamics, drug-drug interactions, resuscitation, cardiology, antiarrhythmics, emergency medicine, patient survival, cardiovascular life support, pharmacology.
Frequently Asked Questions
What is the primary focus of this paper?
The paper focuses on the clinical pharmacology of drugs used during Advanced Cardiovascular Life Support (ACLS), analyzing their mechanisms, systemic effects, and potential drug-drug interactions in the context of cardiac arrest.
What are the main topics discussed?
Key topics include the pharmacodynamics of epinephrine, vasopressin, amiodarone, and lidocaine, the role of ACLS guidelines, the impact of preexisting conditions, and the potential interactions with commonly used cardiac medications.
What is the main goal of the research?
The goal is to provide a deeper understanding of why specific ACLS drugs are administered and to highlight that, while these drugs are essential for resuscitation, they carry significant risks and interactions that should be considered by healthcare professionals.
Which scientific methods are utilized?
The paper utilizes a literature review and comparative pharmacological analysis to evaluate the efficacy of current resuscitation protocols and the physiological impacts of intervention drugs.
What does the main body of the text cover?
It covers the specific mechanisms of vasopressors and anti-arrhythmics, evidence from clinical studies regarding their success rates, and the critical importance of identifying patient comorbidities and current medication regimens during emergency interventions.
Which keywords best describe this study?
Keywords include cardiac arrest, ACLS, pharmacodynamics, drug-drug interactions, epinephrine, vasopressin, amiodarone, and resuscitation.
Why is the case of JG significant in this paper?
The case study of JG illustrates the real-world challenge of performing a "full code" without prior knowledge of the patient's medical history or the specific cause of the cardiac arrest, highlighting the complexity of acute emergency care.
What are the identified risks when using amiodarone?
The paper notes that amiodarone has significant drug-drug interactions, particularly when combined with beta-blockers or calcium channel blockers, and warns that long-term studies on the side effects of short-term IV amiodarone usage are currently lacking.
- Arbeit zitieren
- Antje Dangel (Autor:in), 2014, Cardiac Arrest. The Side Effects of Saving Lifes, München, GRIN Verlag, https://www.hausarbeiten.de/document/303791
